Preferences for Immunotherapy in Melanoma: A Systematic Review Ann LivingstoneAnupriya AgarwalRachael L. Morton Melanoma 29 October 2019 Pages: 571 - 584
ASO Author Reflections: Important Factors for Adjuvant Immunotherapy Treatment Decisions for Stage II–IV Melanoma Patients and Their Clinicians Ann LivingstoneRachael L. Morton ASO Author Reflections 31 October 2019 Pages: 585 - 586
Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy Thomas F. StoopZeeshan AteebMarco Del Chiaro Pancreatic Tumors 27 September 2019 Pages: 587 - 596
ASO Author Reflections: Acceptable Impact of Endocrine and Exocrine Insufficiency on Quality of Life After Total Pancreatectomy Thomas F. StoopMarco Del Chiaro ASO Author Reflections 25 October 2019 Pages: 597 - 598
Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells of Cholangiocarcinoma Patients Yuki KitanoYo-ichi YamashitaHideo Baba Translational Research and Biomarkers 12 August 2019 Pages: 599 - 607
ASO Author Reflections: Clinical Significance of PD-L1 Expression in Both Cancer and Stroma Cells in Cholangiocarcinoma Patients Yuki KitanoHideo Baba ASO Author Reflections 05 November 2019 Pages: 608 - 609
Impact of CD36 on Chemoresistance in Pancreatic Ductal Adenocarcinoma Masahiko KuboKunihito GotohYuichiro Doki Translational Research and Biomarkers 11 October 2019 Pages: 610 - 619
ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36 Masahiko KuboHidetoshi Eguchi ASO Author Reflections 28 October 2019 Pages: 620 - 621